Medrx Co.,Ltd. Logo

Medrx Co.,Ltd.

Develops pharmaceutical formulations using transdermal absorption technology.

4586 | T

Overview

Corporate Details

ISIN(s):
JP3921220004
LEI:
Country:
Japan
Address:
東かがわ市西山431番地7

Description

Medrx Co., Ltd. is a pharmaceutical formulation development company that specializes in creating new dosage forms of medicines. The company's core focus is its transdermal absorption technology, which is used to develop innovative drug delivery systems like patches. These products are designed to improve patient health and quality of life (QOL) by providing alternatives for medications that are difficult to administer orally or by helping to prevent patients from forgetting to take their medicine. Medrx is actively engaged in research and development, managing a pipeline of pharmaceutical candidates that utilize its proprietary formulation technologies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-03-28 08:03
内部統制報告書-第21期(2022/01/01-2022/12/31)
Japanese 23.8 KB
2023-03-28 08:02
有価証券報告書-第21期(2022/01/01-2022/12/31)
Japanese 1.3 MB
2023-03-08 07:01
有価証券届出書(組込方式)
Japanese 407.0 KB
2022-11-11 07:04
確認書
Japanese 8.9 KB
2022-11-11 07:03
四半期報告書-第21期第3四半期(令和4年7月1日-令和4年9月30日)
Japanese 426.6 KB
2022-08-22 08:00
有価証券届出書(組込方式)
Japanese 296.0 KB
2022-08-10 08:17
確認書
Japanese 8.9 KB
2022-08-10 08:12
四半期報告書-第21期第2四半期(令和4年4月1日-令和4年6月30日)
Japanese 412.8 KB
2022-05-13 08:01
四半期報告書-第21期第1四半期(令和4年1月1日-令和4年3月31日)
Japanese 428.1 KB
2022-03-31 08:02
確認書
Japanese 8.8 KB
2022-03-31 08:01
内部統制報告書-第20期(令和3年1月1日-令和3年12月31日)
Japanese 24.0 KB
2022-03-31 08:01
有価証券報告書-第20期(令和3年1月1日-令和3年12月31日)
Japanese 1.2 MB
2021-11-12 07:13
四半期報告書-第20期第3四半期(令和3年7月1日-令和3年9月30日)
Japanese 389.6 KB
2021-08-11 02:00
四半期報告書-第20期第2四半期(令和3年4月1日-令和3年6月30日)
Japanese 432.0 KB
2021-05-18 09:02
有価証券届出書(組込方式)
Japanese 337.1 KB

Automate Your Workflow. Get a real-time feed of all Medrx Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Medrx Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Medrx Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.